Oxazepam 10mg: UK Supply Chain Nearing Collapse

The UK supply chain for Oxazepam 10mg is showing classic signs of impending failure. A combination of declining demand, manufacturer withdrawals, and exclusion from hospital formularies has pushed this medicine into a high-risk category for long-term supply continuity. The market is not just stressed; it is becoming commercially unviable.

This is not speculation. The data paints a clear picture of a product heading towards de facto discontinuation, following a well-trodden path of other legacy benzodiazepines that have disappeared from the UK market.

Demand Overview

National prescribing has fallen by 30-40% since 2021, now standing at a modest ~29,000 items per year. This shrinking demand is geographically concentrated, with a few high-use areas in South East England propping up national volumes. Prescribing is dominated by long-term maintenance patients, with very few new initiations.

**Implication: For manufacturers, this uneven and eroding commercial base is a major disincentive to remain active. **

**Secondary Care & Formulary Position **

A review of major NHS acute and mental health formularies reveals a critical weakness: Oxazepam is almost never listed, stocked, or initiated in secondary care. Hospitals act as a stabilising force for medicines by maintaining stock and creating institutional demand. Without this support, Oxazepam has no formulary protection, no hospital-driven procurement, and no pipeline of new patients. It is supported only by a dwindling base of legacy primary care prescribing.

  • Acute Trusts (UCLH, Leeds, OUH, CUH, GSTT, NUH, MUFT, UHB) - not listed.

  • Mental Health Trusts (SLAM, Oxleas, CNTW, SHSC, Berkshire, DPT) - not listed or non-formulary.

  • Where mentioned, Oxazepam appears only as a drug patients may already be taking, with guidance to switch to diazepam or lorazepam on admission.

This differs sharply from the standard benzodiazepines (diazepam, lorazepam, clonazepam, temazepam, chlordiazepoxide), all of which are routinely used and stocked.

Why this matters

  • Hospitals act as a stabilising force for medicines by maintaining stock, training prescribers, and creating demand.

  • With Oxazepam absent from secondary-care pathways, there are:

    • no new treatment initiations,

    • no formulary protection,

    • no hospital-driven procurement,

    • no incentive for manufacturers to maintain production.

In effect: Oxazepam is clinically “orphaned” within the NHS, supported only by legacy primary-care prescribing.

Supply Chain Status

The supply base has crumbled. Major generic manufacturers and suppliers, including Accord-UK, Kent Pharma, Waymade Healthcare, and DE Pharmaceuticals, have all discontinued their 10mg lines. This has left the UK with only one or two active suppliers, creating a near-monopoly market where any disruption will have a systemic impact. Supply resilience is dangerously low.

  • Historically, multiple companies held product lines, but several have now formally discontinued oxazepam 10mg, including:

    • Kent Pharma

    • Waymade Healthcare

    • DE Pharmaceuticals

    • Accord-UK (important — a major generics supplier)

  • Although additional MA holders still appear in listings, real-world commercial supply has contracted sharply.

  • Current active supply is effectively limited to 1–2 manufacturers/distributors (predominantly Almus/Sandoz and Thornton & Ross).

Implication: The UK market now behaves like a near-monopoly, making it highly sensitive to single-supplier issues. Supply resilience is low, and future disruptions will be harder to manage or mitigate.

Market Signals (Alerts & Price Behaviour)

The signs of active distress are clear and escalating:

  • **Alerts: There were 32 supply alerts for oxazepam 10mg over the last year, a very high volume for a single strength. (vs 7 for 15mg) in the past 12 months **

  • ** Pricing: Some presentations are now £13+ per pack, far above tariff and indicative of constrained supply. Concession pricing risk is rising. Price trends in dashboard data show a steep rise in late 2025, consistent with shortages or supply rationing **

  • ** Stockouts: Pharmacies report stock exhaustion across multiple wholesalers, sometimes after contacting 6 to 7 suppliers.**

  • ** Global Pressure: International alerts suggest broader API/manufacturing pressure, not just UK distribution issues.**

**Implication: The product is already showing signs of active supply stress and market instability. **

Geographic Concentration of Prescribing

  • National map data shows most of England has very low prescribing rates, with only a few high-use hotspots.

  • Concentrated demand tends to:

    • reduce inventory prioritisation by wholesalers

    • diminish economies of scale

    • make manufacturers more likely to discontinue low-volume lines

Implication: This uneven demand further erodes long-term commercial viability.

Overall Risk Assessment & Forward Outlook

The combination of these factors creates a perfect storm for market failure. The product is viable for now, but its long-term sustainability is deeply uncertain.

  • Short Term (1-3 Years): Expect continued availability but with frequent shortages and price volatility. Expect continued concession pricing and periodic supply alerts.

  • Medium Term (3-7 Years): The probability of further manufacturer withdrawals and prolonged national shortages becomes increasingly high due to reduced economic viability

  • Long Term: The medicine is likely to transition to a low-volume, single-supplier product or become dependent on special-order imports before disappearing entirely (similar to other legacy benzodiazepines)

Talk to us

**If you’re concerned about specific fragile market conditions or want to explore risks relevant to your portfolio, please get in touch for a discussion. **